Takeda is already seeing a return on its $5.2 billion swoop for cancer drugs biotech Ariad at the beginning of the year after the FDA approved potential blockbuster brigatinib in lung cancer.

The Japanese pharma has been building a presence in oncology over the last few years through products such as its Adcetris (brentuximab vedotin), and its $5.2 billion acquisition of Ariad at the ...

At ARIAD Psychological Services, Dr. Adodo brings a wealth of experience in conducting comprehensive neuropsychological and psychological evaluations. These evaluations serve as the bedrock in ...

Joan S. Brugge (Ariad Pharmaceuticals Inc., Cambridge, Mass.): "Growth factor activation of receptor protein tyrosine kinases induces tyrosine phosphorylation of MAP kinases (MAPKs). MAPKs have been ...